Please enable Javascript
Leah Lawrence
Leah Lawrence is a freelance health writer and editor based in Delaware.
Articles by Leah Lawrence
String of Recent Approvals Puts Spotlight on Bispecifics
Leah Lawrence
Print
|
October 11, 2023
Here’s what they add to the treatment toolbox for hematologic malignancies.
Read More
How Can We Challenge the Status Quo in Myeloma Research?
Leah Lawrence
Latest Issue
|
September 20, 2023
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Read More
First-line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis
Leah Lawrence
Meeting News
|
September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Read More
Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Read More
Pacritinib Spleen Response Yielded OS Benefit in Cytopenic Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Read More
Event-free Survival at 24 Months in MCL Yielded Expected OS of General Population
Leah Lawrence
Mantle Cell Lymphoma
|
September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Read More
Questions Remain About Role of Hypoxia Related to NHL CAR T-cell Therapy
Leah Lawrence
Meeting News
|
September 10, 2023
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
Read More
Data on T-cell Exhaustion Support Earlier Use of T-cell-based Therapies in Splenic MZL
Leah Lawrence
Meeting News
|
September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Read More
Shorter Duration Induction Venetoclax Feasible for Older, Unfit AML
Leah Lawrence
Acute Lymphoblastic Leukemia
|
September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Read More
T-Cell ALL Overall Survival Differed by Ethnicity, Small Study Showed
Leah Lawrence
Meeting News
|
September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
Read More
Mosunetuzumab Showed Durable Responses for Relapsed or Refractory Follicular Lymphoma
Leah Lawrence
Indolent B-Cell Lymphoma
|
September 1, 2023
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
Read More
What’s Next for MRD in Myeloma?
Leah Lawrence
Myeloma
|
May 31, 2023
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Read More
Target on the Move
Leah Lawrence
Myelodysplastic Syndromes
|
April 12, 2023
Novel targets are under investigation in several types of hematologic malignancies.
Read More
An Unclear Path: What’s the Best Route After CAR-T Failure in B-Cell Lymphoma?
Leah Lawrence
Aggressive B-Cell Lymphoma
|
February 7, 2023
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Read More
Bispecific Antibodies: New Options
Leah Lawrence
Print
|
January 13, 2023
With more bispecific antibodies in development for hematologic malignancies, physicians must determine how best use them.
Read More
Clinicians Tackle the Challenges of MCL
Leah Lawrence
Print
|
December 22, 2022
Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.
Read More
ALL Prognosis in Elderly Patients Has Shown Some Improvement
Leah Lawrence
Meeting News
|
December 20, 2022
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Read More
Study Examines Resistance to Venetoclax Plus Gilteritinib in R/R AML
Leah Lawrence
Acute Myeloid Leukemia
|
December 19, 2022
Researchers have identified possible resistance mechanisms to gilteritinib plus venetoclax in patients with R/R AML.
Read More
MRD Status Linked with Outcomes in Venetoclax-Treated NPM1-Mutated AML
Leah Lawrence
Acute Myeloid Leukemia
|
December 19, 2022
Molecular MRD was strongly prognostic in patients with NPM1-mutated AML who received venetoclax-based non-intensive therapy.
Read More
MRD Profiling Study Reveals Transcriptional Divergence After Transplant for Myeloma
Leah Lawrence
Myeloma
|
December 10, 2022
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Read More
Load More